Shojapour Mana, Asgharzade Samira
Molecular and Medicine Research Center, Arak University of Medical Sciences, Arak, Iran.
Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Iran J Public Health. 2025 Jul;54(7):1399-1410. doi: 10.18502/ijph.v54i7.19146.
Alzheimer's disease (AD) is one of the progressive neurodegenerative diseases, memory impairments and multiple cognitive and behavioral deficits characterize that. We aimed to evaluate the molecular mechanisms involved in the pathogenesis of AD. It introduces the regenerative medicine approach as a novel therapeutic strategy based on the pathogenesis of AD that would be efficient. Our data was collected using databases such as the Web of Science, PubMed, Scopus, and Google Scholar. We summarized the available therapeutic strategies to induce neurodegeneration that can increase the number of neurons and their survival and improve the plasticity of synapses and synaptic activity. There is a different approach to treatment. In first-line treatment, focusing declines the amyloid beta and hypophosphorylated tau protein accumulation. It inhibits acetylcholinesterase, but in regenerative medicine focusing on treatment via gene therapy, cell therapy, and tissue engineering. As a proposed solution for AD in recent years, the use of inhibitors of the pathogenesis of AD is known as a supportive therapeutic approach, but the multi-potential treatment of regenerative medicine has been able to provide promising results in treating neurodegenerative patients.
阿尔茨海默病(AD)是一种进行性神经退行性疾病,其特征为记忆障碍以及多种认知和行为缺陷。我们旨在评估AD发病机制中涉及的分子机制。本文基于AD的发病机制介绍了再生医学方法,认为这是一种有效的新型治疗策略。我们的数据是通过科学网、PubMed、Scopus和谷歌学术等数据库收集的。我们总结了现有的诱导神经退行性变的治疗策略,这些策略可以增加神经元数量及其存活率,并改善突触可塑性和突触活性。治疗方法有所不同。一线治疗着重减少β-淀粉样蛋白和低磷酸化tau蛋白的积累,抑制乙酰胆碱酯酶,但再生医学则侧重于通过基因治疗、细胞治疗和组织工程进行治疗。作为近年来针对AD提出的解决方案,使用AD发病机制抑制剂被认为是一种辅助治疗方法,但再生医学的多潜能治疗已在治疗神经退行性疾病患者方面取得了有前景的结果。